Compare CXAI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXAI | LSTA |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 28.9M |
| IPO Year | 2020 | 2000 |
| Metric | CXAI | LSTA |
|---|---|---|
| Price | $2.43 | $1.49 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 88.2K | ★ 265.5K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | $4,583,000.00 | ★ $35,283,868.00 |
| Revenue This Year | $74.56 | N/A |
| Revenue Next Year | $87.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.09 | $0.99 |
| 52 Week High | $4.88 | $5.07 |
| Indicator | CXAI | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 43.03 |
| Support Level | $2.40 | $1.35 |
| Resistance Level | $4.88 | $2.06 |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 35.45 | 1.72 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. Its cloud-based, mobile-first platform integrates artificial intelligence, automation, and real-time analytics to streamline workplace interactions across people, spaces, and technology. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, Agentic AI Capabilities, and CXAI-VU. The company generates the majority of its revenue from Licenses.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.